Business context and reporting period
This Form 10-Q is filed by GSI Group Inc., not by Novanta Inc.; the supplied filing identifies GSI Group as a Canadian precision photonics and motion-control products company. The quarterly period ended September 26, 2014, with comparisons to September 27, 2013. Amounts below are in U.S. dollars; financial statement amounts are presented in millions unless noted.
GSI reports three segments: Laser Products, Medical Technologies, and Precision Motion. It acquired JADAK in March 2014 and sold certain assets and liabilities of its Scientific Lasers business in July 2014.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Sales | $94.7 | $79.9 | $270.7 | $234.7 |
| Gross profit / margin | $39.7 / 41.9% | $34.2 / 42.8% | $110.4 / 40.8% | $98.0 / 41.8% |
| Operating income from continuing operations | $6.8 | $5.8 | $17.4 | $12.7 |
| Income from continuing operations | $5.1 | $2.2 | $11.4 | $5.3 |
| Net income attributable to GSI | $4.5 | $1.8 | $6.2 | $3.0 |
| Diluted EPS from continuing operations | $0.15 | $0.07 | $0.33 | $0.15 |
- Reported sales rose 18.5% in Q3 and 15.3% year to date. Excluding JADAK and currency effects, sales decreased 0.5% in Q3 and increased 0.5% year to date.
- Operating margin was 7.2% in Q3 versus 7.3%; year-to-date it was 6.4% versus 5.4%. Precision Motion’s gross margin fell to 41.9% in Q3 from 48.2%, while Medical Technologies’ increased to 39.6% from 38.2%.
- Cash from continuing operations was $34.4 million for the nine months, down from $41.3 million. Capital expenditures were $3.8 million. Cash and equivalents were $53.5 million at quarter end, versus $61.0 million at year end 2013.
- Debt totaled $121.9 million: $36.9 million term loans and $85.0 million revolver borrowings. The revolving commitment was $175 million, leaving $90 million available. Net debt was approximately $68.3 million.
- The company reported compliance with debt covenants: actual leverage ratio 2.07 against a 3.00 maximum; fixed-charge coverage 4.11 against a 1.50 minimum.
Material changes versus prior comparable periods
- JADAK added $14.9 million of Q3 sales and $32.6 million of nine-month sales. The acquisition cost $93.7 million net of working-capital adjustments and was largely funded with revolving-credit borrowings. It contributed $2.3 million of operating income for the post-acquisition nine-month period.
- Medical Technologies’ reported sales rose 65.7% in Q3 and 37.3% year to date, primarily reflecting JADAK. However, the segment recorded operating losses of $1.1 million in Q3 and $1.2 million year to date, with acquired-intangible amortization and weaker visualization sales weighing on results.
- Laser Products sales increased 2.4% in Q3 and 6.6% year to date. Precision Motion sales rose, but its gross margin weakened amid product mix and lower air-bearing-spindle demand.
- Interest expense increased with higher average debt and interest rates. Foreign-exchange results improved from losses in 2013 to gains of $1.0 million in both the quarter and nine-month period.
- Nine-month cash from continuing operations declined partly because the prior-year comparison included a substantial IRS tax refund and favorable working-capital movements.
Outlook, commentary, risks and unusual items
- Management gave no specific numerical revenue or earnings guidance. It stated that expected operating cash flows should fund operating and investing needs for at least the next 12 months, with the revolver available as an additional liquidity source.
- Management cited medical-equipment spending softness, delayed product introductions, and an OEM customer’s dual sourcing as headwinds for visualization products. Laser growth reflected fiber-laser customer wins and CO2 product launches; Precision Motion benefited from encoder gains but faced weaker spindle demand.
- The Scientific Lasers sale generated approximately $6.5 million cash proceeds, with $1.5 million held in escrow through January 2016. The nine-month discontinued-operations loss included a $3.0 million write-down of that business and a $0.5 million write-down of the India joint venture; the company was negotiating to dissolve the joint venture.
- A $5.4 million escrow recovery related to the NDS acquisition reduced goodwill. JADAK’s preliminary purchase-price allocation included $45.0 million goodwill and $40.3 million identifiable intangible assets; the allocation remained subject to adjustment.
- Key disclosed risks include cyclical customer capital spending, order timing, product development and commercialization, acquisition integration, foreign-exchange and interest-rate movements, supplier disruptions, debt requirements, and the ability to access subsidiary cash. Management reported effective disclosure controls and no material change in internal control during the quarter. Ordinary-course legal matters were not expected to have a material adverse effect, though outcomes were not assured.
Most important facts for investors to verify
- Confirm the issuer identity: the filing is for GSI Group Inc., despite the request metadata naming Novanta Inc.
- Assess underlying growth separately from acquisition-driven growth; reported Q3 sales rose while organic sales declined slightly.
- Track Medical Technologies’ operating losses and visualization-product demand, and whether JADAK contributes sustained earnings after acquisition costs and amortization.
- Review cash conversion, debt balances, borrowing availability, covenant headroom, and the company’s capacity to fund future acquisitions and debt service.
- Monitor the Scientific Lasers escrow and India JV wind-down, as well as final adjustments to JADAK’s purchase accounting.